Multiple sclerosis, now comes the cure at home

Worldwide, 2.8 million people live with multiple sclerosis, over 130 thousand in Italy alone, where the incidence is about 3,400 new cases per year in the youngest and most productive group of society (20-40 years), with a double Prevalence in women as in men. Patients who can treat neurodegenerative disease at home. The last drug for which Aifa authorized reimbursement, the first high-efficiency home treatment (Het, High Efficiency Therapy), which is administered once a month at home itself, marks a step forward in the provision of treatments between house walls. This is what is published in an article in ‘Allies for Health’, the portal dedicated to medical-scientific information created by Novartis.

Home care is a particularly relevant aspect when you consider that multiple sclerosis, a disease of the central nervous system, the normal functioning of the brain, optic nerves and spinal cord is impaired by inflammation and loss of nerve tissue, leading to varying degrees of physical, emotional and social impairment. Early diagnosis is not easy because the disease presents with very varied symptoms, which can also change with time both in duration and in intensity. Among the most common: visual disturbances, fatigue and exhaustion (fatigue), balance and walking difficulties, lack of strength, tingling and sensitivity problems.

About 85% of people initially diagnosed have the relapsing remitting formwhich is characterized by acute episodes of illness (relapse) alternating with periods of complete or partial well-being (remissions), and for which the new highly effective care at home (Het) is now available.

They stand out three forms of multiple sclerosis: primary progressive (Smpp), relapsing-remitting (Smrr) and second progressive (Smsp). The latter comes from an initial course of Smrr and is characterized by physical and cognitive changes over time, in the presence or absence of relapse, leading to an accumulation of neurological impairment. In the field of multiple sclerosis – we read in the article – today we achieve the goal of therapies for the various stages of the disease indicated: from its manifestations in the pediatric age to the advanced stages of its development.

In particular, the medicine for which Aifa recently approved the reimbursement by the National Health Service responds to a significant unmet clinical need for people living with relapsing remitting multiple sclerosis as it is the first highly effective therapy, targeting B lymphocytes, which can be easily self-administered, once a month at home. The ability to perform treatment at home, with great flexibility, is a significant advantage in terms of quality of life and direct and indirect costs for the NHS: Thanks to home therapy, patients can now significantly reduce the time to face treatment, with a favorable effect on social and working life.

The home, for multiple sclerosis, is increasingly a nursing home, as provided by the NRP, not only for treatments but also for services that can help the patient manage their pathology. In fact, they are precisely designed for people with multiple sclerosis Patient television modelsArtificial intelligence solutions for the monitoring of various parameters were promoted and free drug delivery and support services for medical staff were created.

In contrast to other neurological and neurodegenerative diseases, which mainly affect the elderly population, Multiple sclerosis often occurs between 20 and 30 years of agein 10% of cases at the age of 18 with profound social implications because it affects school education, professional and relational life and, in general, autonomy, given that over time the patient may require continuous help.

The full article is available at:

Leave a Comment